PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced its new partnership with plant-based professional athlete and Chicago Bears quarterback Justin Fields. According to the update, Fields will serve assist in promoting the company’s brand and product offerings and help advocate for the benefits of living a plant-based lifestyle. The young quarterback’s successful sports career kick-started when he was playing college football with University of Georgia Bulldogs in 2018, which led him to the Ohio State Buckeyes in 2019. He won two First-Team All-Big Ten Conference Awards during his time with Ohio State. His talent and perseverance led to him being drafted as a quarterback and 11th overall player by the Chicago Bears of the National Football League in 2021. While taking part in a challenge with his family at the beginning of the COVID-19 pandemic, Fields decided to adopt a plant-based diet that excludes meat and dairy products. Since then, he has experienced the benefits and has become a strong advocate of plant-based eating and its positive effects on sports performance. “Living a plant-based lifestyle at first was just a short-term challenge, which quickly turned into a passion and way of life for me,” said PlantX Ambassador, Justin Fields. “PlantX is the perfect destination for people looking to educate themselves and try new products that are plant based.”
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at www.PlantX.com and the PlantX investor website at https://Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality (“AR”) for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events, has received an order for 35 AR labs from Ryerson University. A widely recognized leader in higher ed, Ryerson has more than 46,000 students. The university ordered the reality labs for use in its biology, chemistry and biochemistry departments. The announcement noted that the additional labs will increase Ryerson’s AR lab offerings to students by 70%. Nextech anticipates completing the order later this year and noted that, when complete, Ryerson University Faculty of Science will have one of the largest known AR immersive learning programs in the world. The 35 new labs will be added to the 50 labs developed for the 2020–21 school year as well as the AR labs produced through the RALE AR Lab Builder Program. Nextech’s EdTechX platform provides the use of AR for education institutions. Built on Microsoft Azure and approved on the Azure marketplace as a co-sell ready partner, EdTechX and its proprietary services transforms traditional learning and event formats into valuable, immersive digital experiences. “We are thrilled to see the hard work we have done in creating AR labs for students in partnership with Ryerson result in such a hugely positive response from both students and faculty,” said Nextech CEO Evan Gappelberg in the press release. “We have developed not just an immersive AR learning platform but also a unique business model for Nextech with a credit system where one credit is equivalent to one AR lab, which costs $5,000 each. Once the AR labs are created along with the AR Lab Builder Program, through a Government of Ontario Initiative in Partnership with Ryerson University and Nextech, all AR labs built will be available province-wide to institutions of higher education in 2022. We are extremely excited and gratified to be working with both Ryerson and the government to bring immersive learning experiences to Canadian students.”
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.
Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, please visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Net Element’s (NASDAQ: NETE)post-merger company, Mullen Technologies Inc., has entered into a letter of agreement with Height Dispensary LTD to purchase 1,200 Mullen ONE electric vans, an agreement worth an estimated $60 millon; the LOA also noted that Height has selected Mullen as its exclusive provider for electric vehicles (“EVs”). Net Element isa financial technology company in the process of becoming a pure-play electric vehicle manufacturer through a pending definitive agreement with privately held Mullen Automotive Inc., an emerging electric vehicle manufacturer. Texas-based Heights specializes in high-quality legal CBD and THC products online with plans to open a retail cannabis dispensary. The first 200 Mullen ONE vans are slated for delivery on or before the end of Q3 2023, with the additional 1,000 vehicles purchased by Q2 2025. The Mullen ONE EV Cargo Van vehicles are a modified version of the Mullen FIVE, an electric crossover SUV based on a skateboard EV platform and unibody frame. “We’re very excited that Heights Dispensary has selected Mullen to satisfy all its electric vehicle needs,” said Mullen Technologies CEO and chairman David Michery in the press release. “The Heights order is the second, among many other companies we are currently working on, to select Mullen as their EV provider. The FIVE skateboard platform allows us to configure and offer the vehicle for many different types of commercial trade uses.”
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the United States, the company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM) and by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
NetworkNewsWire Editorial Coverage: One of the most pervasive diseases in first-world countries, heart disease is the leading causeof death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (“CDC”), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don’t even know they have it. The urgency of finding effective treatments for this life-threatening disease can’t be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).
High blood pressure is a life-threatening disease that can be managed with effective treatment.
Lexaria is a first mover in developing potential treatment base on its DehydraTECH technology.
The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
Recent human clinical study using DehydraTECH technology demonstrated rapid, sustained drop in blood pressure along with excellent tolerability.
Hypertension Running Wild
Controlling blood pressure is essential to health. High blood pressure is a primary or contributing cause of death in almost 500,000 deaths a year, and hypertension can double the risk of a heart attack and quadruple the chance of having a stroke, plus raise the likelihood of heart failure, vision loss, renal disease, dementia, peripheral artery disease and more. And it’s not just an “old-person” problem; nearly one in four adults aged 20 to 44 have high blood pressure. In addition, high blood pressure costs the United States about $131 billion each year.
The good news? The disease can be managed — and even cured — with effective treatment. With that in mind, it’s no surprise that the global anti-hypertensive drugs market is expected to grow from $24.17 billion in 2020 to $27.81 billion in 2025. Even with current hypertension drugs available, only 24% of the 108 million people in the U.S. with high blood pressure have their condition under control. It’s a market ripe for innovation.
Increasing Onset, Bioavailability, Potency
Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space. The Kelowna, British Columbia-based company has developed and patented its DehydraTECH technology, a drug-delivery platform for increasing the speed of onset, bioavailability and drug potency. The mechanics involve combining an active pharmaceutical ingredient (“API”) with fatty acid oil and then applying the mix to carrier particles, which can even be common ingredients such as tapioca starch or gum arabic. Next, a patented dehydration synthesis procedure is performed, and the product is rendered as powder or liquid for use in the desired final form factor, such as a pill, tablet, chewable or oil.
Lexaria has been working with National Research Council of Canada, the biggest R&D organization in the country, since 2017 on defining the qualities of DehydraTECH. Among other things, Nuclear Magnetic Resonance molecular characterization suggests DehydraTECH does not change the chemical structure of an API it delivers, which is critical in reliance on original API safety data in developing novel delivery methods without starting from scratch regarding the FDA process. This keeps the door open to a faster path to market.
Ultimately what this means is DehydraTECH could make lower doses of some substances more effective while even reducing side effects. The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
Early Results Show Extreme Promise
Just last month, Lexaria announced that a human clinical study using DehydraTECH technology demonstrated a rapid and sustained drop in blood pressure along with excellent tolerability. “We are very encouraged by these early results in our 2021 hypertension program,” said Lexaria CEO Chris Bunka. “Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in stage 2 hypertensive volunteers.”
Initial results show that blood pressure was reduced across both male and female volunteers and was most pronounced in the first 10–50 minutes of the study treatment, reinforcing pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic controls. Dr. Phil Ainslie, the lead investigator on the study, commented that “these early results are extremely promising in this at-risk hypertensive population and provide a fundamental support for expansion into more prolonged repeat dosing and future longer term clinical trials.
Platform Diversification
Lexaria’s vision and focus is on several core business segments for DehydraTECH, including heart disease and hypertension, reduced-risk noncombusted nicotine and improved antiviral drug delivery, to name a few. Multiple successes on different fronts have been reported recently, including work in the antiviral program where DehydraTECH has been used to process compounds from leading drugs used for antiviral drugs for SARS-CoV-2/COVID-19 and HIV/AIDS. This is critical work not only for hopefully treating COVID-19 today but also in order to be better prepared when the next pandemic inevitably comes (think bird flu, swine flu, MERS, SARS, etc.).
The scalability to address a diverse group of market opportunities lends color to the potential of DehydraTECH. Consider the antivirals market that is in the spotlight right now because of the COVID-19 pandemic and the circulating delta variant is estimated at $52.1 billion and forecast to reach $66.7 billion by 2025. But DehydraTECH is so versatile, there are many other potential applications. Lexaria sees opportunities in human hormones (e.g., testosterone and estrogen replacement, a $21.9 billion market); oral mucosal nicotine (global smokeless tobacco products market valued at $13.6 billion in 2018), vitamin D3 ($1.1 billion market); PDE5 inhibitors ($4.4 billion market in 2014); and non-steroidal anti-inflammatories ($15.6 billion market in 2019).
Cardiovascular Disease Market Only Getting Bigger
Lexaria is only tapping into a slice of the $92.4 billion cardiovascular drug market that generates billions of dollars in profits every year for drug makers. Majors dominate this lucrative market expected to rise to $107.77 billion in 2025, fueled by a return to normal healthcare practices in a post-pandemic economy.
Pfizer Inc. (NYSE: PFE), one of the largest pharmaceutical companies in the world, notes that despite advances in care and treatment, cardiovascular disease (“CVD”) remains the number-one cause of death worldwide, with the prevalence only expected to increase. Pfizer is committed to harnessing its legacy and expertise as it aims to address gaps in CVD treatment through the development of new medicines that can meaningfully reduce CV risk for patients. Originally manufactured by Pfizer, NORVASC(R) has been available for more than 25 years and is prescribed to treat high blood pressure (hypertension), certain types of chest pain (angina), and blocked arteries of the heart (coronary artery disease).
Merck & Company Inc. (NYSE: MRK)announced earlier this year that the FDA had granted approval to its (and Germany-based partner Bayer’s) heart-failure drug, Verquvo (vericiguat). The company noted that patients with symptomatic chronic heart failure and reduced ejection fraction have a high risk for hospitalization after experiencing symptoms of heart failure requiring outpatient IV diuretic treatment or hospitalization. Many of those, perhaps even more than half, are hospitalized within a month of discharge due to a worsening event, and approximately one in five dice within two years. The approval of VERQUVO provides doctors, health-care professionals, and patients with a new option to current available therapies.
Novartis AG (NYSE: NVS), like most other majors, is highly diversified, with its top-20 products generating $16 billion in sales during the first half of 2021. Entresto, its drug to reduce the risk of cardiovascular death and hospitalization for heart failure in certain patients, was its biggest gainer during Q2, with sales surging 53% from the year prior quarter to $886 million during the quarter. Novartis is committed to reimagining medicine and using innovative science and technology to address some of society’s most challenging healthcare issues.
AstraZeneca PLC (NASDAQ: AZN) announced in April that its proprietary sodium-glucose cotransporter 2 (SGLT2) inhibitor, Farxiga, has been approved for use in the United States. In phase 3 trials, the drug demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death. Chronic kidney disease is often associated with a heightened risk of heart disease or stroke, and the company called the approval of Farxiga, one of the most significant advancements in the treatment of chronic kidney disease in more than 20 years.
Heart disease is the most indiscriminate killer in the United States. Every year it is a leading cause of death for men, women and people of most racial and ethnic groups. About one in every four deaths is caused by heart disease, equating to roughly 655,000 Americans each year. It’s clear that drug sales are booming trying to combat it, but any innovation to make these medicines (many of which have ugly side effects) better will almost certainly be welcomed with open arms.
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Tuesday, August 3rd, 2021UncategorizedComments Off on $LEXX Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space
InMed has a world class leadership team with a successful track record of drug development and commercialization
The company recently announced closing of a $12 million private placement
InMed has a solid and expanding intellectual property portfolio with multiple patents filed
The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica
InMed retains all commercial rights to its IntegraSyn manufacturing system
InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa
The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029
InMed Pharmaceuticals (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.
The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.
Research and Technology
There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (“CBN”) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”).
Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (“API”) in InMed’s two lead programs for dermatological and ocular diseases.
InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.
InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.
Manufacturing
The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.
BayMedica Inc. Acquisition
On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.
As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.
Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.
Market Outlook
There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.
Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.
Management Team
Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).
Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.
Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.
Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.
Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
Infobird (NASDAQ: IFBD), a software-as-a-service (“SaaS”) provider of artificial intelligence (“AI”) powered or enabled customer engagement solutions in China, today announced its entry into a service contract with a subsidiary of a globally well-recognized Fortune 500 retail and consumer product company. According to the update, the new client is a renowned leader in retail and consumer products, with operations in more than 80 countries around the world. Under the contract, the client will leverage Infobird’s intelligent quality inspection to comprehensively upgrade its customer service system in China and bring the ultimate consumer experience to users by creating professional, caring and convenient integrated services. The cooperation represents another major breakthrough in IFBD’s market development strategy, demonstrating Infobird’s successful expansion into the market of retail and consumer product companies.
Infobird, headquartered in Beijing, China, is a software-as-a-service provider of innovative AI-powered or enabled customer engagement solutions. For more information about the company, visit www.Infobird.com.
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at http://ibn.fm/IFBD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Ideanomics (NASDAQ: IDEX), a company focused on the convergence of financial services and industries experiencing technological disruption, today announced that it has pledged $25 million to support minority and underserved communities, driven by the company’s continued environmental, social and governance (“ESG”) commitment. “Enabling financial empowerment has been the common thread for all businesses under Ideanomics Capital,” said Alf Poor, CEO of Ideanomics. “We are excited to join a network of progressive supporters of the MDI Keepers Fund. This is a proactive investment we are putting into communities that require the most disruption and transformation. We believe this fund will allow us to continue supporting diversity in our subsidiary businesses while maximizing the impact to these communities.”
In addition, Ideanomics has completed its acquisition of privately held US Hybrid, a manufacturer and distributor of electric powertrain components and fuel cell engines for medium and heavy-duty commercial fleet applications. Material details of the terms are disclosed in the company’s related 8-K filing. The completed acquisition marks another critical milestone in Ideanomics’ mission to reduce commercial fleet greenhouse gas emissions through forward-thinking partnerships and advanced electronic vehicle (“EV”) technologies. Roth Capital Partners LLC acted as financial advisor for the offering.
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under an innovative sales-to-financing-to-charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and shareholders with the opportunity to participate in high-potential growth industries. For more information, visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Tuesday, August 3rd, 2021UncategorizedComments Off on $IDEX Pledges $25M to Support Minority and Underserved Communities, Closes Acquisition of US Hybrid
FingerMotion (OTCQX: FNGR), a mobile data and services company, announced that the OTC Markets Group informed the company that it had become aware of promotional activities in the United States regarding shares of FNGR’s common stock. OTC Markets requested FingerMotion comment on the activity. In the announcement, FingerMotion observed that the company was made aware of promotional activity encouraging investors to purchase FNGR stock the same day — July 28, 2021 — that OTC Markets had contacted the company. In response, and on the same day, FingerMotion released a press release regarding its application to have its common stock listed on the Nasdaq Capital Market. The company noted that certain promotional materials in the form of a newsletter had been prepared and distributed by parties the company was unaware of; FingerMotion was not involved in the activity and had no control over the newsletter content. According to the announcement, the company noted that it does not believe any information contained in the promotional materials was false or misleading. “However, it is possible that certain excerpts might be read as misleading and/or incomplete, and readers should not place undue reliance on the promotional materials,” the press release stated. “The company is not able to comment on information about the industry or the market as we cannot determine the accuracy or legitimacy of the sources. Specifically, the company does not condone the use of sensational language to describe the company’s business prospects or the growth potential of the company’s industry. The company notes that investing in the company’s securities involves certain risks and uncertainties which investors should review prior to making any investment decision.”
FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. FingerMotion is one of only a few companies in China with access to wholesale rechargeable minutes from China’s largest mobile phone providers that can be resold to consumers. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at http://ibn.fm/FNGR
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Recently published research shows that the use of cannabis is not independently linked to a loss of motivation among adolescents. The study was conducted over a two-year period by a team of researchers associated with the Florida International University. Study results were published in the Journal of the “International Neuropsychological Society.”
The study’s authors note that a decrease in motivation is commonly mentioned as a consequence of marijuana. However, prior studies have largely centered on adults and have yielded different results. For their study, the researchers recruited more than 400 subjects aged between 14 and 17. Each subject had to complete a quintet of biannual assessments during the study.
The investigators evaluated the motivation of each participant by using two self-reported questionnaires: the Motivation and Engagement Scale and the Apathy Evaluation Scale, which comprise of subscales that measure the value, self-effectiveness, planning, persistence and disengagement that the subjects place on school. In addition, the investigators asked every participant about their use of tobacco, cannabis and alcohol during each evaluation and conducted an analysis of the data to model patterns of motivation and the use of marijuana over time.
The study’s raw results show that the use of marijuana grew considerably, as did the lack of engagement and motivation. The greater use of marijuana was linked to less valuing of school, lower planning and more disengagement. It should be noted, however, that once the data was controlled for variables including the effects of other factors such as depression, sex and age, as well as the participants’ reported use of tobacco and alcohol, the team discovered little evidence that the use of marijuana had an effect on motivation.
In their report, the study’s authors stated that their findings didn’t support a relationship between a decline in motivation and the use of marijuana over time. The researchers also noted that the study didn’t show a loss of motivation over time, even when respondents reported a considerable increase in the use of marijuana.
The researchers explained that the change in the use of marijuana didn’t forecast changes in motivation, despite the increase in the levels of marijuana use, which proposes that the use of marijuana may not cause a decline in motivation over time. The researchers also noted that future study will continue to examine these links longitudinally in order to determine if heavier levels of marijuana use leads to a decrease in motivation.
In a press release, NORML deputy director Paul Armentano stated that these findings served to destroy outdated stereotypes about marijuana.
It looks like the cannabis industry, including players such as Flora Growth Corp. (NASDAQ: FLGC) have one less myth to contend with, thanks to the research done by the Florida International University team.
NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at http://cnw.fm/FLGC
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
A new study suggests that the general public’s perception of the possible harms of psilocybin mushrooms doesn’t align with drug laws. The study found that magic mushrooms were considered to be less dangerous in comparison with tobacco, alcohol and other substances. The study was published in the “Journal of Psychopharmacology.”
The study’s author, professor Carl Roberts from the department of psychology at the University of Liverpool, stated that he was greatly interested in how substances affected an individual’s behavior as well as their brain. He explained that he had been following research on the therapeutic potential of psychedelic substances such as psilocybin, adding that he knew that the data on the actual harm of the use of psilocybin mushrooms proposed that the substance’s abuse potential and toxicity was low. However, he continued, the substance was still classified as a Schedule 1 drug in the United States, which suggests that it is just as harmful as cocaine and heroin.
Roberts revealed that his interest in finding out the general public’s perception of harms around psilocybin mushrooms and whether they aligned with scientific evidence or the government’s legal classifications is what led to the study being conducted.
For their research, the researchers recruited more than 150 participants from different social media pages and websites that provide information on recreational drug use. Roughly 20% of them came from the United States while about one-half of the remaining number were from the United Kingdom. The remainder were from other countries in the European Union.
The researchers discovered that most participants considered psilocybin mushrooms to be relatively safe, in comparison with the other substances. This is despite the fact that psilocybin mushrooms are classified as a Class A substance in the U.K. and a Schedule I substance in the U.S.
The participants who had never used psilocybin listed it as the second-least dangerous substance while those who had used these mushrooms prior to the study listed it as the least dangerous substance from the list. The non-users listed marijuana as the least dangerous substance. Roberts explained that their findings proposed that the general perception of psilocybin mushroom harm aligned with scientific data on their toxicity and abuse potential as well as the relative harms of magic mushrooms that are scientifically recognized.
He notes though that the study had some limitations, including the potential of selection bias as it was an online survey style study.
That notwithstanding, the positive public perception of psilocybin means that when companies such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) bring to market medicines or products relating to psilocybin, the public reception is likely to be warm from the get-go.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Shares of The Alkaline Water Company Inc. (NASDAQ:WTER) traded today at $2.17, eclipsing its 52-week high. This new high was reached on below average trading volume as 608,000 shares traded hands, while the average 30-day volume is approximately 2.3 million shares.
Alkaline Water Co Inc is engaged in the business of distributing and marketing bottled alkaline water for retail consumers in different sizes. The firm sells its product in 500ml, 700ml, 1-liter, 1.5-liter 3-liter, and 1-gallon sizes. Its only operating geographical segment being the United States of America. The company sells its product to convenience stores, natural food products stores, large ethnic markets, and national retailers.
In the past 52 weeks, shares of The Alkaline Water Company Inc. have traded between a low of $0.93 and a high of $2.17 and is now at $2.14, which is 130% above that low price.
The Alkaline Water Company Inc. (NASDAQ:WTER) defies analysts with a current price ($2.14) 8.6% above its average consensus price target of $1.96.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Monday, August 2nd, 2021UncategorizedComments Off on $WTER Rise to a New 52-Week High
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, has reported second-quarter financial results for the period ended June 30, 2021. Noteable numbers include the announcement that UUUU has $98.8 million — $79.4 million in cash and marketable securities and $29.2 million in inventory — working capital and that the company saw a net loss of $10.8 million, which included a non-cash, mark-to-market increase in warrant liabilities of $3.6 million resulting from a significant increase in the company’s share price. The report also noted that Energy Fuels is ready to provide uranium for the proposed U.S. Uranium Reserve once it is established by the U.S. government as well as for markets around the world. The company reported that it has begun ramping up to commercial-scale production of a mixed rare earth element (“REE”), actually delivering RE carbonate to a European separation facility last month. UUUU has also entered into a definitive agreement to sell a package of Energy Fuels’ non-core conventional uranium projects and has entered into a strategic alliance agreement to evaluate the recovery of thorium and potentially radium from the company’s RE carbonate and uranium process streams. The company will be hosting a results webcast on Aug. 3, 2021, at 4 p.m. ET to discuss its Q2 2021 financial results as well as its rare earth production and other corporate initiatives. Interested individuals can dial 1-888-664-6392 (toll free in the United States and Canada) to participate on the call. A recording of the call will also be available on the company website until Aug. 27, 2021. “The outlook for uranium also continues to improve, vanadium markets are strengthening and REE prices continue to exhibit strength,” said Energy Fuels president and CEO Mark S. Chalmers in the press release. “With three fully licensed uranium processing centers — the White Mesa Mill and the Nichols Ranch and Alta Mesa in situ recovery facilities — the largest NI 43-101 resource portfolio among U.S. uranium producers, and almost 700,000 pounds of U.S.-produced U3O8in inventory, the company remains well-positioned to benefit from a strengthening uranium market and the proposed U.S. Uranium Reserve once it is established by the U.S. government. But what I find most exciting about all this is that not only do we have excellent optionality and exposure to improved uranium markets, we are also leveraging our existing uranium assets to give the company and our shareholders exposure to vanadium, REEs and potentially medical isotope markets, all as complements to our primary uranium business. Each of these complementary businesses could develop into a significant business for the company in its own right and bodes well for our quickly developing ‘Critical Minerals Hub’ in the U.S.”
Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 (“U3O8”)to major nuclear utilities. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up to commercial-scale production of RE carbonate. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of more than 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101-compliant uranium resource portfolios in the United States and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced its plans to host a conference call to discuss its Q2 2021 results. According to the update, SRAX’s CEO and Founder Christopher Miglino and CFO Michael Malone will provide an operational and financial summary of Q2 2021 on a video call, with a live question-and-answer session, at 4:30 p.m. ET / 1:30 p.m. PT on Monday, August 16, 2021. Interested parties should visit https://ibn.fm/CLYIh to register for the live webcast and view the presentation. Attendees can access the conference by phone by dialing +1 346-248-7799 and entering meeting ID: 93255970733 and passcode: 163778. The webcast will be available on www.SRAX.com for at least 90 days.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and www.MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Despite its youth and immaturity, America’s state-legal cannabis industry has been dubbed one of the fastest-growing sectors in the country. The sector has generated billions of dollars in revenue for businesses and provided jobs for hundreds of thousands of people. In addition, projections have the space pulling in $43 billion by 2025. Cannabis is a high-risk industry and potentially a high-reward industry, especially for companies that can weather the risks, and many businesses are looking to throw their hats into the ring.
Michigan, for instance, legalized recreational cannabis only one and a half years ago, and its large population coupled with favorable cannabis policies make it an increasingly attractive market. Since last April, Michigan’s recreational cannabis sales have exceeded $100 million, and cannabis sales are expected to surpass $1.2 billion this year. According to projections by the 2021 MJBizFactbook, recreational sales in Michigan are set to quadruple from around $500 million in 2020 to roughly $2 billion–$2.5 billion in 2025.
Presently, Michigan has an estimated 200 recreational cannabis stores, putting it at one dispensary for every 34,000 residents. According to Frank Colombo, the director of data analytics for Viridian Capital Advisors, the state has little market penetration and is still in a “process of consolidation.” As such, interested cannabis companies can pitch tent in Michigan’s recreational cannabis sector with relatively little competition, at least for the moment. In fact, a report that was recently released by the New York-based Cowen Group states that Michigan is home to one of the biggest cannabis markets in the country.
The state’s cannabis policies make its cannabis space enticing to businesses in the cannabis space. For starters, Michigan currently has unlimited licensing on a statewide basis, which has led to lower acquisition prices compared to states such as Illinois. This allows established businesses as well as new entrants to acquire other cannabis operators without having to break the bank. On the municipal level, however, the state has seen several municipalities opt out of launching legal markets. While more municipalities are expected to opt in over time, probably with licensing caps, limiting licenses will allow existing businesses to retain their market share and profitability for longer without having to contend with competition.
Thanks to an uptick in cultivation facilities, there are fewer cannabis flower shortages, and flower is more affordable than it was when Michigan first launched its recreational industry. Beginning Oct. 1, 2021, the state will also reduce its licensing fees from $25,000 to $7,500, which, coupled with cheaper cannabis flower, will reduce operational costs.
NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
A mandate from the Centers for Medicare and Medicaid Services directed that from Jan. 1, 2021, all hospitals in the United States provide pricing information online about their services and items. The objective of this mandate is to help inform patients about the cost of procedures and services before they receive them.
Researchers from Brigham and Women’s Hospital and Massachusetts Eye and Ear used this data to examine price variation and transparency for thyroid cancer treatment. They discovered that both price and transparency differed greatly, with the costs of various services having huge variations and only one-half of the cancer centers included in the study revealing negotiated prices.
The study’s results were reported in the “JAMA Network” journal.
Roy Xiao, an otolaryngology-head and neck surgery resident at the institution and the study’s corresponding author, stated that revealing negotiated prices was crucial in assisting patients in estimating the cost of care before treatment was administered. Xiao added that while the researchers expected some degree of variation based on prior research, the range they observed was astonishing.
The study centered on thyroid cancer because the treatment of this particular cancer is known to impose huge financial burdens on patients. Rates of bankruptcy are the highest for patients with thyroid cancer, in comparison to other patients who suffer from other types of cancer. The scientists distinguished price variation and availability for thyroid care in more than 50 NCI-designated centers (National Cancer Institute) in their study. Of this number, half revealed commercial payer-negotiated prices for any services or items.
The researchers observed extensive differences across centers, even after they normalized factors that affect the cost of delivery of care, disclosing that there was a 44-fold variation in the neck-computed tomography costs and a 70-fold variation in radioactive iodine treatment costs. They added that, on average, procedures such as a thyroid uptake scan and a fine needle aspirate biopsy differed by roughly 5-fold among the centers.
The researchers note that while the Centers for Medicare and Medicaid Services requires hospitals to reveal negotiated rates for physicians employed by the institution, physicians who practice at these hospitals are usually employed by associate physician organizations, which may explain why many centers don’t disclose surgeon professional fees for thyroid surgery. They also observe that their research was carried out shortly after these price-transparency requirements were implemented, which means that transparency and disclosure rates may increase as more centers comply with the mandate. The study’s senior author, Rosh K.V. Sethi, asserts that price transparency will help both physicians and patients understand differences in cost.
The disparities in the costs incurred by thyroid cancer patients make a strong case for personalizing treatment modalities in the way that is exemplified by what companies such as Predictive Oncology (NASDAQ: POAI) are doing since a customized protocol stands a higher chance of improving patient outcomes, thereby lowering costs incurred in the long term.
NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Lexaria just completed dosing for its second human clinical study, HYPER-H21-2
The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD
The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States
Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan
It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes
Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as it works towards achieving its business plan objectives. At the beginning of the year, the company set out to conduct three human clinical studies, two of which are underway at the time of this article. Its most recent human clinical study, HYPER-H21-2, dosing was completed in July 2021 and was designed to understand better the human response to Lexaria’s DehydraTECH 2.0-enabled CBD (https://cnw.fm/Tzr2W). The company projects that preliminary results would be available for reporting either in September or earlier.
This second human clinical trial involved 16 human volunteers who previously dealt with hypertension or were mildly hypertensive at the time of the study. Each of the 16 participants received three different doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo for a total dose of 450 mg. the study involved a 24-hr continuous ambulatory (portable) monitoring of vitals such as blood pressure and heart rate, while also taking into consideration evaluations of central arterial stiffness, physical activity as well as sleep quality.
Lexaria hopes to commence with the third and last human clinical hypertension study of 2021, HYPER-H21-3. It will offer updates in due course.
As the company celebrates the progress achieved through this second human clinical trial, Lexaria marked another massive milestone by increasing its market reach in the United States (“US’). With partnerships with Cannadips, New World CBD, Impact Naturals and Amari, among others, Lexaria’s DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the US (https://cnw.fm/yg4Fv).
In an official statement from Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, he noted that “Lexaria technology is enabling increased market share and sales growth for our continually growing list of corporate clients. We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”
Lexaria is a global leader in enhancing the overall speed and efficiency of orally-delivered fat-soluble active molecules and drugs. With its drug delivery technology and its advancing intellectual property (“IP”), the company is transforming existing consumer products and medications that may improve their availability and bioavailability. Its flagship technology, DehydraTECH(TM), improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of the fat-soluble active molecules.
As of early July 2021, Lexaria had 20 patents falling under 13 different patent families. In July, it got its second patent in Japan titled “Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof.” This became the company’s 21st patent granted to the company and the 17th patent granted to its first patent family.
Also, in July, Lexaria received US$3,817,643 from warrant exercises. The company issued the warrants in relation to its January 2021 public underwritten offering. Under this offering, the shares and warrants issued were registered according to a Form S-1 Registration Statement. They were excised into 580,189 shares of voting common stock of the company at an exercise price of US$6.58 per share (https://cnw.fm/dmMfb).
Lexaria noted that all proceeds received from the warrant exercises would be used to continue advancing the company’s investigational research program and for general corporate purposes.
With these critical milestones achieved so far, Lexaria is confident that its business plan objectives, along with all its operations, are now all set and fully funded, well into the 2022.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
Ideanomics (NASDAQ: IDEX), a company focused on the convergence of financial services and industries experiencing technological disruption, today announced that it has made a strategic investment in Prettl Electronics Automotive (“PEA”). According to the update, PEA is a business unit within the Prettl Group, a large German industrial company that manufactures and distributes components and systems for the automotive, energy and electronics industries. The deal terms include a strategic investment of €7.5M (~$9M) for a 30% ownership stake, under which Ideanomics will receive exclusive sales and distribution rights for PEA charging infrastructure products and solutions in North America. In addition, IDEX CEO Alf Poor will join PEA’s board of directors. “The opportunity to work with Prettl brings together two companies with a global perspective for what is required to bring EV mobility solutions to global markets. The PEA team’s innovative approach, both in terms of potential to deploy high-power charging infrastructure and the dynamic load balancing of charging by energy requirements at an individual vehicle level, is among the most progressive EV charging solutions we have seen,” said Ideanomics CEO Alf Poor. “PEA fulfills a critical component of our EV enablement strategy, and we look forward to supporting them as both an investor and as a regional partner. PEA greatly adds to the family of products, services and technologies we are assembling that are synergistic, in-demand and high-value, and ultimately positions Ideanomics to capture revenues and market share throughout the commercial EV value chain.”
The company also announced its appointment of Shane McMahon as the executive chairman of the board. Per the update, Jim Cassano will become the new vice chairman. McMahon has been involved with IDEX since 2010, and previously served as vice chairman. “Shane has been an inspirational and passionate leader for Ideanomics, and we are honored to have him as our executive chairman,” said Ideanomics CEO Alf Poor. “His entrepreneurial approach and marketing acumen have been vital to our recent and anticipated growth. We are excited to be able to leverage his broad business and organizational understanding as we scale the company in the U.S. and globally.”
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under an innovative sales to financing to charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and shareholders with the opportunity to participate in high-potential growth industries. For more information, visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Monday, August 2nd, 2021UncategorizedComments Off on $IDEX Announces Strategic Investment in Prettl Electronics Automotive, Executive Chairman Appointment
A recent study published in the “Consciousness and Cognition” journal has found that language produced while an individual is under the influence of LSD shows decreased semantic coherence and increased entropy levels. In layman’s terms, this means that people were more likely to move from one topic to another and have more disorganized speech while under the influence of LSD.
Entropy was developed by physicists to quantify lost energy in mechanical systems. However, researchers have found that this measure of randomness and uncertainty in a system can also be used to measure spontaneous activity in brain networks.
Study author Enzo Tagliazucchi, who is als the director of the Consciousness, Culture and Complexity Lab and a professor at the University of Buenos Aires, stated that a few years ago, it was proposed that the effects of psychedelic substances were brought about by increased disorganization of patterns of brain activity. He noted that the hypothesis was strongly supported by neuroimaging experiments in people, which led to speculation that increased entropy levels could also have an effect on natural language production. This is what prompted the researchers to study whether psychedelic substances had a disorganizing effect on natural speech.
For their study, the researchers recruited 20 healthy participants who either received a dose of placebo or a dose of LSD before undergoing magnetoencephalography (“MEG”) and functional magnetic resonance imaging (“fMRI”) scans at a neuroimaging laboratory. Each participant had to visit the lab twice, with each visit being two weeks apart. In addition to this, each participant was interviewed by the researchers regarding their feelings and thoughts during the experience.
The researchers then used computer algorithms to conduct an analysis of the participant’s speech patterns, which led them to the discovery that in comparison to those under the influence of placebo, participants under the effects of LSD scored higher on speech disorganization. The researchers also found that while the latter group tended to use more words while under the influence of LSD, their vocabulary was relatively smaller.
In their report, the researchers note that the order of dosing was randomized, adding that the study had some limitations, including the fact that the participants could easily make out whether they had consumed the placebo or LSD. This, the researchers explained, changed the participants’ attitude toward the experiment. They note that subjects tend to speak more while under the influence of LSD in comparison with those under the effects of the placebo.
The diverse (both good and potentially adverse) effects of psychedelic compounds such as LSD may explain why sector players including Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) prefer to concentrate their R&D efforts on developing medicinal formulations to be administered under the watchful eye of trained medical professionals.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
The global cancer diagnostics market is expected to reach $249.6 billion by 2026
AnPac Bio-Medical Science Co. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.
AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.
Cancer Differentiation Analysis (“CDA”)
Cancer Differentiation Analysis (“CDA”) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.
Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.
CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.
AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.
Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:
Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.
Market Outlook
AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.
According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://ibn.fm/EMdoS). The market is expected to grow at a CAGR of 7% during the forecast period.
Management Team
Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.
Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.
Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.
Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.
For more information, visit the company’s website at www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care. “We believed in 3a’s research and development plan from the beginning, when we signed the first collaboration contract in 2020. Now that XPhyto has announced the pending acquisition of 3a, we are particularly excited about this development milestone,” said Wolfgang Probst, director and COO of XPhyto. “Successful validation of the first biosensor candidates demonstrates the expertise and scientific excellence at 3a. Since the co-developed and successfully approved German CE marked 25-minute PCR test in March of this year, this novel approach for oral biosensor screening is another important milestone towards development of tools to effectively identify infectious breakouts of COVID-19 to reduce the pandemic spread and help find our way back to the new normal.”
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
SRAX Inc. (NASDAQ: SRAX) Releases Suite of Tools Designed to Help Bridge Gap Between Listed Corporations and Investors
Registered Investment Advisors and retail investors cumulatively account for significant proportion of US equity market assets under management
SRAX’s Sequire platform bridges gap between corporations and their end investors
SRAX recently introduced automated email and SMS functions, allowing companies to efficiently communicate with millions of retail investors on their platform
Listed companies will also be able to search and interact with investment advisor community through Sequire’s proprietary search functions
Investment advisors make up a huge segment of the U.S. investor base; according to a recent survey carried out by RIA Channel, there were 14,955 independent registered investment advisors in the United States with cumulative assets under management of $2.969 trillion (https://ibn.fm/gkVER). Meanwhile, retail investors have increasingly become a dominant force within the U.S. equity market; a study carried out by Morgan Stanley revealed that retail investors accounted for close to 10 percent of daily trading volume on the Russell 3000, the broadest U.S. stocks index, after peaking at 15% in September 2020 as widespread lockdowns and increased savings triggered interest in the markets (https://ibn.fm/ecxI4). SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has sought to bridge the gap between listed corporations and the two investor sub-sets through the introduction of a number of novel features on its platform.
As of May 2021, SRAX revealed that its Sequire platform had seen its corporate subscriber base swell to 183 publicly listed companies in addition to boasting a network of over five million influential, forward-thinking investors and shareholders. Sequire has recently released new features to help facilitate communication between its listed corporate subscribers and retail investor base, consisting of an automated email feature as well as an SMS function.
Sequire’s listed corporate base will have access to custom filters to assist them in structuring campaigns directed at specific investor categories (https://ibn.fm/mmDe2), along with automation triggers, machine learning and other enhancements designed to promote frictionless communication between corporations and the millions of retail investors on their platform.
“These new tools will allow companies to better manage communication with their shareholder base by defining pre-established triggers that will execute both email and SMS messages,” said SRAX Founder and CEO Christopher Miglino (https://ibn.fm/u0ITG).
SRAX has simultaneously released new search features, enabling companies to access contact information on registered investment advisors. Banking on the knowledge that close corporate interactions with investment advisors make it more likely that a given investment advisor will recommend a company’s stock to clients, the investment advisor feature on Sequire will seek to assist issuers in developing significant connections and ties with the investment advisor community (https://ibn.fm/0deuy).
SRAX’s corporate subscribers will be able to search and filter for specific types of advisors, designed to assist them in efficiently contacting their target audience. Moreover, in addition to assisting issuers in communicating with the advisors, the platform will also enable companies to track their subsequent participation in their listed equity.
“Registered Investment Advisors have been the largest investors in our company SRAX and have been a significant part of the growth of our shareholder base. We are now providing the tools that will enable issuers to identify, communicate with and track the progress of specific advisors,” stated Christopher Miglino.
For more information, visit the company’s websites at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Wednesday, July 28th, 2021UncategorizedComments Off on $SRAX Releases Suite of Tools Designed to Help Bridge Gap Between Listed Corporations and Investors
Save Foods (NASDAQ: SVFD) is an agri-food tech company focused on food safety and creating innovative solutions for food waste and loss. ReFED, a national nonprofit dedicated to ending food loss and waste across the U.S. food system by advancing data-driven solutions, estimates that 24% of all food in the U.S. — 54 million tons — goes to landfill, incineration, down the drain or is left in the fields to rot. “Save Foods offers the first natural product with the potential to actually replace the different chemicals with a maximum residue level used today while also addressing the challenges of both food waste and food safety,” notes a recent article. “The company’s natural treatments protect fresh fruit and vegetables from microbial spoilage and foodborne pathogens that are responsible for decay and can cause foodborne illnesses, while leaving no harmful residues on the produce or in the environment. ‘Fresh produces treated with our products can already be found in different supermarket chains across the U.S. and Europe where it was reported that Save Foods products are reducing by 50% on average the rotten fruit at the retail level,’ the company reports.”
Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops new solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and the consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing house processing, including citr`fruits, avocado, mango, pears, apples, and bell pepper. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, but they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co.
NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at http://ibn.fm/SVFD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), a diversified leading provider of augmented reality (“AR”) solutions and services, has announced plans to release its second-quarter 2021 financial results on Aug. 11, 2021, after markets close. The company will also host a conference call to discuss its financial numbers and results on Aug. 12, 2021, at 1 p.m. ET. Nextech CEO Evan Gappelberg and CFO Andrew Chan will host the call and provide an overview of company financial and operating results; the call will also include a question-and-answer period. Interested individuals can call in toll-free by dialing (877) 201-0168 — (647) 788-4901 for international callers — and using the conference ID 2086367. The call is also available in webcast format. A recording of the presentation will be available on the company’s website following the conclusion of the call.
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.
Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, please visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reached a significant point in its second human clinical study of 2021: HYPER-H21-2. The company announced that dosing has been completed in the study, which was comprised of 16 human volunteers who were pre- or mildly hypertensive; each participant received three separate doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo. The study also included 24-hour continuous monitoring of blood pressure and heart rate, as well as evaluations of central arterial stiffness, physical activity and sleep quality. This key information will be assessed to evaluate the human response to DehydraTECH 2.0-enabled CBD. The company anticipates beginning a third human clinical study, HYPER-H21-3, following analysis of results from the first and second studies. In addition, Lexaria announced the expansion of its intellectual property portfolio with the allowance of its second patent in Japan. The patent is the 21st patent the company has been granted. Lexaria also noted that more than 7,000 stores across the country sell products that use its exclusive DehydraTECHtechnology. Some of those products include Cannadips, the original tobacco-free and nicotine-free CBD pouch; a growing number of New World CBD SKUs; and next-generation CHYLOSOMA(TM) formulations of CBD, CBG and CBN topical skin offerings. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” said Lexaria CEO Chris Bunka. “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”
Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit http://www.LexariaBioScience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at http://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Wednesday, July 28th, 2021UncategorizedComments Off on $LEXX Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products
Shares of Flora Growth Corp. (NASDAQ:FLGC) traded at a new 52-week high today of $6.60. This new high was reached on above average trading volume as 940,000 shares traded hands, while the average 30-day volume is approximately 655,000 shares.
Flora Growth Corp is a vertically integrated cannabis company. It is focused on becoming the largest producer of low-cost naturally grown medicinal-grade cannabis oils, CBD-infused foods and beverages, and pharmaceutical-grade medical and cosmetic-grade derivatives from the cannabis plant. It prioritizes organic ingredients and value-chain sustainability across its portfolio to create products that help consumers restore and thrive.
Based on a current price of $5.76, Flora Growth Corp. is currently 12.0% above its average consensus analyst price target of $5.07.
In the past 52 weeks, shares of Flora Growth Corp. have traded between a low of $2.85 and a high of $6.60 and is now at $5.76, which is 102% above that low price.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Wednesday, July 28th, 2021UncategorizedComments Off on $FLGC Shares of Flora Growth Rise Above Previous 52-Week High
FingerMotion (OTCQX: FNGR), a mobile data and services company, has submitted its application to have shares of its common stock listed on Nasdaq Capital Market. The company will now look to receive NASDAQ approval of the move as well as work to satisfy applicable listing, governance and regulatory requirements. During the NASDAQ review process, the company’s common stock will continue to trade on the OTCQX using the current symbol FNGR. “Over the past year, we have been working diligently to comply with certain uplisting requirements,” said FingerMotion CEO Martin Shen in the press release. “Applying for a NASDAQ listing is a key milestone in our company’s evolution. We believe listing our common stock on the Nasdaq Capital Market will improve liquidity, increase our corporate visibility and enhance shareholder value. We are excited to have submitted this application, which if approved, would see us join the ranks of global technology companies listed in the U.S. We look forward to updating shareholders on our progress in due course.”
FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at http://ibn.fm/FNGR
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) today provided an update on the ongoing drilling program at the Silver City Project located in Saxony, Germany. Among the highlights, the company reported smooth commencement of drilling at the first of four priority targets of the 12,000-metre diamond drilling program planned for 2021. In addition, a second drill rig was added to the program, with drilling now underway at the Peter Vein (Neue Hoffnung Gottes) and Bräunsdorf (Christbescherung) targets. “We have had another smooth startup of drilling at Silver City this year,” said Ben Pullinger, SVP Geology & Corporate Development. “We continue to appreciate the support of the local community and benefit from the excellent work of the TU Bergakademie Freiberg and the Helmholtz Institute of Freiberg. This year’s program builds on discoveries made last year in the first modern-day drilling for precious metals on the Bräunsdorf license. Our current drilling focusses on the historically productive gneiss-schist contact running through the Bräunsdorf and Peter Vein mines. In the coming weeks we will move up to the mafic-schist contact intersected last year at Reichenbach and Grauer Wolf, both of which yielded some of the most interesting results from drilling to date.”
Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. Additional details on Excellon’s properties are available at www.ExcellonResources.com.
NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at http://ibn.fm/EXN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application
Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates
Cybin is confident this added focus will better enable the evaluation of patient outcomes
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy.
“The digital therapeutics platform, which is proprietary to Cybin and the subject of the company’s 13th patent application, adds another dimension to the company’s development programs,” the announcement said. “The aim of utilizing and leveraging cutting-edge technologies to support drug-development candidates will be a top priority as both the industry and the company evolve.”
Already a recognized leader in progressing psychedelic therapeutics, Cybin is looking to evolve its programs beyond the psychedelic molecule into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development. In a strategic approach to accomplishing this objective, the company created a patient steering committee that, as part of the Cybin innovation team, is focused on the next phase of the digital therapeutics platform.
Cybin is confident this added focus will better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for better pre- and post- psychedelic treatments. Other steps the company has taken recently to strengthen its presence in the market include collaborations with Kernel and its quantitative neuroimaging technology and Greenbrook TMS, the operator of 129 outpatient mental health service centers in the United States. The company is also working to advance other proprietary tools such as the EMBARK psychotherapy model.
These efforts are all focused on Cybin’s commitment to building an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.
Cybin operates under the principle that psychedelic therapies offer a novel approach to mental health care that is focused on treating the underlying conditions and improving the patient experience and outcome. Recognizing that a paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, the company is at the forefront of exploring all that psychedelics offer. “We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape,” the company states.
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (‘GBM’). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021,” reports an article discussing the status of the study to treat GBM, an aggressive type of brain cancer with most treatments only slowing progression and reducing symptoms. “Berubicin is a novel therapy for GBM and the first anthracycline to cross the blood-brain barrier and kill cancerous tumor cells in humans. The Phase 1 safety trial for Berubicin was conducted by another company 14 years ago. Since then, one patient has lived cancer-free, with two others seeing a reduction in tumor size by up to 80%. . . . With the serious unmet medical need for new GBM treatments, CNS Pharmaceuticals applied for and was granted FDA Fast Track Designation for Berubicin. According to CNS Pharmaceuticals CEO John Climaco, receiving Fast Track Designation is a major achievement for the advancement of Berubicin for the treatment of the most aggressive, deadly and treatment-resistant type of brain cancer. ‘Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ he explained.”
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
AmpliTech Group (NASDAQ: AMPG), a radio frequency (“RF”) component designer and manufacturer, recently released its Q1 report, which reflected record bookings, a record backlog and the fact that it achieved design wins reflecting its low noise amplifier (“LNA”) products’ performance, durability and heat dissipation. “While the LNA products provide significant value and return on investment for satellite network applications in space, AmpliTech sees other exciting applications,” reads a recent article. “Recently, AmpliTech received a developmental order for a special cryogenic-cooled probe head used to facilitate studies on materials, molecules and drugs to treat diseases.” According to CEO and CTO Fawad Maqbool, the company expects to benefit from the mass reopening of its market segments with the steady decline in COVID-19. “To support the substantial opportunities we have identified, we completed a recapitalization of our company over the first four months of 2021, providing over $30M in current funding to support our growth and demonstrate financial strength to our customers and partners. Additionally, we also uplisted our common stock to Nasdaq to position our company for greater visibility, liquidity and access to a much broader pool of potential investors.”
AmpliTech Group designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G & IoT), space, defense and quantum computing markets, as well as provides systems and component design consulting services. AmpliTech has a 13+ year track record of developing high-performance, custom solutions to meet the unique needs of some of the largest companies in the global industries it serves. The company is proud of the unique skills, experience and dedication of its focused team, enabling AmpliTech to deliver superior solutions, faster time to market, competitive pricing, and excellent customer satisfaction and repeat business. For more information about the company, visit www.AmpliTechinc.com.
NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at http://ibn.fm/AMPG
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
